Cohance Lifesciences Ltd (COHANCE) is currently trading at 339.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals, operates primarily as a CDMO serving global life sciences and fine chemical majors. They provide services covering Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. The company is actively enhancing its capabilities and widening its product offerings, especially focusing on ADCs and oligonucleotides, both seeing substantial global demand, evidenced by strong engagement with top global innovators. Cohance's strategic focus is on capacity expansion and technology aggregation, reflected in recent investments, including those in NJ Bio and Sapala Organics, boosting their operational and R&D capabilities in advanced biotechnology domains. Despite recent challenges, including plant shutdowns and the global biotech funding landscape, Cohance maintains a forward-looking outlook, anticipating improvements and growth backed by deferred shipments and new project engagements. Significant mid and long-term growth is expected from their strong pipeline, comprising diverse and advanced R&D projects, alongside strategic geographical expansion, especially in the US and Europe.

Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹334.40 and a high of ₹1,328.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Cohance Lifesciences Ltd has a market capitalization of approximately 12,984.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Cohance Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.86 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Cohance Lifesciences Ltd (COHANCE) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 12,984.33 Cr, Cohance Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Cohance Lifesciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 37.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Cohance Lifesciences Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.

Key risks associated with Cohance Lifesciences Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.